Completed PHASE4 INTERVENTIONAL 2-arm NCT01523301

Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients

Double Blind, Placebo-controlled, Parallel, Multicenter, Randomized Interventional Phase IV Study to Evaluate the Efficacy of Rotigotine on Depressive Symptoms in Idiopathic Parkinson's Disease Patients

Sponsor: UCB Korea Co., Ltd.

Conditions Idiopathic Parkinson's Disease

Interventions Placebo Rotigotine

Updated 7 times since 2017 Last updated: Nov 16, 2015 Started: Apr 30, 2012 Primary completion: Oct 31, 2014 Completion: Oct 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Idiopathic Parkinson's Disease and is currently completed. UCB Korea Co., Ltd. leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Apr 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

UCB Korea Co., Ltd.

Data source: UCB Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ansan, South Korea , Anyang, South Korea , Busan, South Korea , Daegu, South Korea , Daejeon, South Korea , Goyang, South Korea , Gwangju, South Korea , Gyeonggi-do, South Korea , Jinju, South Korea , Jungbuk, South Korea and 2 more locations